Market Cap (In JPY)
52.29 Billion
Revenue (In JPY)
-
Net Income (In JPY)
-2.64 Billion
Avg. Volume
3.23 Million
- Currency
- JPY
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 380.0-1489.0
- PE
- -
- EPS
- -
- Beta Value
- 0.352
- ISIN
- JP3336750009
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Keita Mori MBA
- Employee Count
- -
- Website
- https://www.sanbio.jp
- Ipo Date
- 2015-04-08
- Details
- SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
More Stocks
-
FOSECOINDFoseco India Limited
FOSECOIND
-
CMIG3
-
MCOT
-
1379Hokuto Corporation
1379
-
FLEXO
-
HERF
-
KAP
-
PAOTFParrot S.A.
PAOTF